RYZODEG 70/30 Drug Profile
✉ Email this page to a colleague
Summary for Tradename: RYZODEG 70/30
Recent Clinical Trials for RYZODEG 70/30
Identify potential brand extensions & biosimilar entrants
Sponsor | Phase |
---|---|
Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
Novo Nordisk A/S |
Recent Litigation for RYZODEG 70/30
Identify key patents and potential future biosimilar entrants
District Court Litigation
Case Name | Date |
---|---|
Novo Nordisk Inc. v. Alvogen, Inc. | 2022-03-03 |
NOVO NORDISK INC. v. SANDOZ INC. | 2020-06-04 |
Novo Nordisk Inc. v. Sandoz Inc. | 2020-06-03 |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for RYZODEG 70/30 Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for RYZODEG 70/30 Derived from Company Disclosures
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
---|---|---|---|---|---|---|---|
Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | See Plans and Pricing | 2016-06-20 | Company disclosures |
Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | See Plans and Pricing | 2021-01-05 | Company disclosures |
Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | See Plans and Pricing | 2023-08-05 | Company disclosures |
Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | See Plans and Pricing | 2024-10-21 | Company disclosures |
Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | See Plans and Pricing | 2021-01-05 | Company disclosures |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for RYZODEG 70/30 Derived from Patent Text Search
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
---|---|---|---|---|---|---|---|
Novo Nordisk Inc. | RYZODEG 70/30 | insulin degludec and insulin aspart | Injection | 203313 | See Plans and Pricing | 2031-10-25 | Patent claims search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for RYZODEG 70/30
Country | Patent Number | Estimated Expiration |
---|---|---|
Denmark | 1909870 | See Plans and Pricing |
Norway | 985981 | See Plans and Pricing |
Norway | 2018002 | See Plans and Pricing |
Canada | 2738877 | See Plans and Pricing |
China | 1509193 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for RYZODEG 70/30
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
122013000062 | Germany | See Plans and Pricing | PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND INSULIN ASPART IN ALLEN DURCH DAS BASISPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/12/806/001 EU/1/12/806/004-005 EU/1/12/806/007-008 20130121 |
92226 | Luxembourg | See Plans and Pricing | PRODUCT NAME: COMBINATION D'INSULINE DEGLUDEC ET INSULINE ASPARTE SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; FIRST REGISTRATION DATE: 20130121 |
300596 | Netherlands | See Plans and Pricing | PRODUCT NAME: INSULINE DEGLUDEC; NATIONAL REGISTRATION NO/DATE: EU/1/12/807/004 20130123; FIRST REGISTRATION: EU EU/1/12/807/001 20130123 |
92213 | Luxembourg | See Plans and Pricing | PRODUCT NAME: INSULINE DEGLUDEC SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/12/807/001-4-5-7-8-9-12-13-15 TRESIBA 20130123 |
138 5015-2013 | Slovakia | See Plans and Pricing | PRODUCT NAME: INZULIN DEGLUDEK; REGISTRATION NO/DATE: EU/1/12/807/001 - EU/1/12/807/015 20130121 |
>Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |